Lipigon secures US patent for treatment of cardiometabolic disease
This is an English translation of the Swedish original. In case of discrepancies, the Swedish original shall prevail.
Lipigon Pharmaceuticals ("Lipigon") today announces that the US Patent and Trademark Office (USPTO) has granted a patent covering Lipisense® for the treatment of cardiometabolic disease.
Lipigon has obtained final approval from the US Patent and Trademark Office (USPTO) for their pioneering approach of targeting the ANGPTL4 protein with the RNA drug Lipisense® for the treatment of cardiometabolic disease.
Lipisense® is a drug candidate for the treatment of diseases characterized by abnormal lipid levels in the blood, primarily triglycerides, and represents a first-in-class treatment with a unique mechanism of action. Elevated triglyceride levels in the blood are a risk factor for several diseases, and Lipisense® has demonstrated its ability to reduce these levels in both preclinical and clinical studies.
The US patent, numbered 17/667,449, protects the use of antisense oligonucleotides targeting specific sequences of ANGPTL4 mRNA for reducing ANGPTL4 expression as the treatment of cardiometabolic disease. This includes obesity, diabetes, hypercholesterolemia, hypertriglyceridemia (HTG), dyslipidemia, pancreatitis, metabolic syndrome, and familial chylomicronemia syndrome (FCS). The patent will be valid until 2039.
"Securing the US patent for the treatment of cardiometabolic disease is a significant achievement for Lipigon. It represents a crucial step in safeguarding the intellectual property rights of the program. Given that the US is the largest pharmaceutical market globally, this development holds important strategic importance for our company," says CEO Dr. Stefan K. Nilsson.
Earlier this year Lipigon successfully completed the phase I clinical study for Lipisense®. The company is now preparing for phase II clinical trials.
About Lipisense®
Lipisense® is an RNA therapeutics drug candidate that prevents the cells from producing the disease-promoting target protein ANGPTL4 in the liver by destroying the protein-coding RNA before the target protein has been formed. Genetic data demonstrate that ANGPTL4 is an independent risk factor for both cardiovascular disease and type 2 diabetes.
For more information, please contact:
Stefan K. Nilsson, CEO, Lipigon
Email: [email protected]
Phone: +46 705 78 17 68
About Lipigon
Lipigon Pharmaceuticals AB is a clinical-stage pharmaceutical company developing drugs with new, unique mechanisms of action (first-in-class) for diseases caused by disorders in the body's handling of fats. The company's operations are based on over 50 years of lipid research at Umeå University, Sweden. Lipigons initial focus is on orphan drugs and niche indications, but in the long term, the company has the possibility to target broader indications, such as diabetes and cardiovascular disease. Lipigons pipeline includes four active projects: the RNA-drug Lipisense® for the treatment of hypertriglyceridemia, an RNA drug for the treatment of acute respiratory distress syndrome, a gene therapy treatment for the rare disease lipodystrophy in collaboration with Combigene AB (publ), and a small molecule program for the treatment of dyslipidemia in collaboration with HitGen (Inc). Read more at www.lipigon.se.
The company's share (LPGO) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.
Om Lipigon
Prenumerera
Få löpande information från Lipigon via e-post.
